Tag Archives: CONVALESCENT PLASMA SUCCEEDS

Two gold-standard trials published in The New England Journal of Medicine on Wednesday help settle questions about two controversial therapies touted by many early in the pandemic with decidedly mixed results – failure for the antiparasite drug ivermectin and success for antibody-rich blood plasma from COVID-19 survivors. In Brazil, 3,515 patients with symptoms of COVID-19 for a week or less …

Read More »